CAPTRUST Financial Advisors
PRQR icon

CAPTRUST Financial Advisors’s ProQR Therapeutics PRQR Stock Holding History

CAPTRUST Financial Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,500
Closed -$6K – 3531
2022
Q2 		$6K Buy
+7,500
New +$5.59K ﹤0.01% 4012
2021
Q4 		– Sell
-7,500
Closed -$63K – 4876
2021
Q3 		$63K Hold
7,500
– – ﹤0.01% 2430
2021
Q2 		$51K Hold
7,500
– – ﹤0.01% 2499
2021
Q1 		$50K Buy
+7,500
New +$38.3K ﹤0.01% 2433

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAPTRUST Financial Advisors's PRQR Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of ProQR Therapeutics (PRQR) in Q3 2022, closing a stake of 7,500 shares — an estimated $6K sold.

CAPTRUST Financial Advisors first reported a position in PRQR in Q1 2021 and held it in 4 quarters. The position peaked at $63K in Q3 2021. 47 funds tracked by Wall St. Rank hold PRQR as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining ProQR Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 7,500 ProQR Therapeutics shares in Q3 2022, an estimated $6K.
  • CAPTRUST Financial Advisors first reported a position in ProQR Therapeutics in Q1 2021 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's ProQR Therapeutics position peaked at $63K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.